| scholarly article | Q13442814 |
| P2093 | author name string | Yanming Wang | |
| Song Li | |||
| Wu Zhong | |||
| Xinbo Zhou | |||
| Shiyong Fan | |||
| P2860 | cites work | SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. | Q50904360 |
| Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix. | Q53152142 | ||
| Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. | Q54342129 | ||
| Antibody-drug conjugates. | Q54407980 | ||
| Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate | Q80901453 | ||
| The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma | Q84560547 | ||
| Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members | Q21195197 | ||
| New developments for antibody-drug conjugate-based therapeutic approaches | Q26766540 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells | Q28201813 | ||
| Unraveling the role of proteases in cancer | Q33838143 | ||
| Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications | Q34223494 | ||
| Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 | ||
| HER2-directed therapy: current treatment options for HER2-positive breast cancer | Q35551522 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma | Q37606966 | ||
| Investigational antibody drug conjugates for solid tumors | Q37877745 | ||
| Beyond trastuzumab: new treatment options for HER2-positive breast cancer | Q37947902 | ||
| Linker technologies for antibody-drug conjugates | Q38126424 | ||
| Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer | Q38169649 | ||
| Current ADC Linker Chemistry | Q38373185 | ||
| HER2-targeted antibody drug conjugates for ovarian cancer therapy | Q38752699 | ||
| Strategies and challenges for the next generation of antibody-drug conjugates | Q39182945 | ||
| Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates | Q40279317 | ||
| Dipeptide-based highly potent doxorubicin antibody conjugates | Q40353611 | ||
| Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. | Q41655720 | ||
| Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice | Q41735350 | ||
| Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity | Q44066317 | ||
| HER2 aberrations in cancer: implications for therapy | Q44936056 | ||
| Micro- and mid-scale maleimide-based conjugation of cytotoxic drugs to antibody hinge region thiols for tumor targeting | Q45244928 | ||
| Cathepsin B Cleavage of vcMMAE-Based Antibody-Drug Conjugate Is Not Drug Location or Monoclonal Antibody Carrier Specific | Q46596240 | ||
| Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload | Q47139670 | ||
| Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography | Q47864055 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2017-08-25 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload | |
| P478 | volume | 18 |
| Q92040902 | An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates |
| Q47103332 | Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment |
| Q64072797 | Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy |
| Q91747362 | Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy |
| Q92165417 | Synthesis and Biological Evaluation of RGD and isoDGR-Monomethyl Auristatin Conjugates Targeting Integrin αV β3 |
Search more.